Express Pharma

Ajanta Pharma posts Rs 438 crore consolidated revenue in Q2 of FY 2015-16

0

EBITDA growth was at Rs 154 crore

Ajanta Pharma has reported its performance for the second quarter and half year ended September 30, 2015. The second quarter consolidated revenue states that operations grew 18 per cent at Rs 438 crore against Rs 372 crore. The company posted EBITDA growth of 19 per cent at Rs 154 crore against Rs 129 crore. Profit before tax grew 24 per cent at Rs 147 crore against Rs 119 crore. Profit after tax grew 20 per cent at Rs 100 crore against Rs 83 crore.

The half yearly consolidated result stated that revenue from operations grew 20 per cent at Rs 829 crore against Rs 694 crore. EBITDA growth of 22 per cent was at Rs 276 crore against Rs 226 crore. Profit before tax grew 28 per cent at Rs 265 crore against Rs 206 crore and profit after tax grew 29 per cent at Rs 184 crore against Rs 143 crore.

Yogesh M Agrawal, Managing Director, Ajanta Pharma said, “Despite challenges posed by currency devaluation’s in most of the emerging markets, we have delivered sound performance in these geographies. We continue to post above industry growth in Indian market with utmost focus on brand building.  To accelerate product filings, we are increasing spend levels in R&D which ensures sustained growth in future.”

Comments are closed.